Pō a AoHealing Sanctuary · Knowledge Library
All pages

Veterans · Service members · Families

You are more than
what happened to you.

A respectful place to research PTSD, moral injury, depression, addiction, medicines, safety, family support, and the full journey before and after an experience.

A place to start—not another promise

Service can end. What you carry may not.

You deserve information that does not reduce you to a diagnosis or use military identity as a marketing story. Pō a Ao brings research, medicine questions, provider roles, preparation, family support, and integration into one path.

Potential benefits studied

What people hope for.
What the evidence actually says.

These are positive outcomes reported in research—not promises. Each medicine has a different evidence level, population, legal status and safety profile. The full page names exactly what was measured, who was studied and what remains unproven.

01

Ibogaine

Preliminary observational evidence

Potential positive findings

Reported reductions in PTSD, depression and disability/functioning scores after a combined magnesium–ibogaine protocol in 30 male Special Operations Forces veterans; lower withdrawal and drug-use-severity scores in small non-veteran cohorts.

Essential limit

Not randomized, not controlled, not ibogaine alone and not proof of durable benefit. Serious cardiac and neurologic risks—including deaths—are documented.

02

Ketamine

Short-term depression evidence; PTSD result differs

Potential positive findings

Moderate evidence for rapid short-term depression-score reduction in general adult trials. In 158 veterans and service members with resistant PTSD, a secondary depression measure improved.

Essential limit

The same veteran trial did not show benefit for core PTSD symptoms. Racemic ketamine, esketamine, compounded products and retreats are not interchangeable.

03

MDMA-assisted therapy

Promising investigational therapy-package signal

Potential positive findings

Two phase 3 trials reported larger short-term reductions in PTSD symptoms and functional-impairment scores for pharmaceutical MDMA plus structured psychotherapy than placebo plus the same therapy.

Essential limit

Not FDA-approved. Pivotal samples were chiefly civilian; no veteran-only efficacy result was reported. FDA identified effectiveness, safety and data-quality uncertainties.

Need Help?